Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies

Alinaghi, Farzad; Calov, Monika; Kristensen, Lars Erik; Gladman, Dafna D.; Coates, Laura C.; Jullien, D.; Gottlieb, Alice B.; Gisondi, Paolo; Wu, Jashin J.; Thyssen, Jacob P.; Egeberg, Alexander

doi:10.1016/j.jaad.2018.06.027

Cited by 432 publications

(322 citation statements)

References 271 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…A systematic review revealed 14.0%-22.7% of psoriasis patients having arthritis PsA in psoriasis patients [35]. PsA is characterized by enthesitis and arthritis in peripheral and axial involvement with bone proliferation and erosion [36,37].…”

Section: Psoriatic Arthritismentioning

confidence: 99%

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Kamata

Tada

2020

IJMS

153

116

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders. Furthermore, an association with cardiovascular events is indicated. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different. Better understanding of those characteristic leads to the right choice for individual patients, resulting in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.

show abstract

Section: Psoriatic Arthritismentioning

confidence: 99%

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Kamata

Tada

2020

IJMS

153

116

View full text Add to dashboard Cite

show abstract

“…Psoriatic arthritis (PsA) is part of the spondyloarthritis spectrum and affects 10–30% of people with psoriasis . Patients with PsA may have enthesitis, synovitis, and osteitis, in addition to variable skin involvement, resulting in a highly heterogeneous clinical presentation.…”

Section: Introductionmentioning

confidence: 99%

Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

Siebert

Sweet

Dasgupta

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. To evaluate the associations of C-reactive protein (CRP) and circulating Th17-associated cytokine levels with psoriatic arthritis (PsA) disease activity and therapeutic response to ustekinumab.Methods. Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927). In post hoc analyses, relationships of IL-17A, IL-17F, and CRP levels at baseline, week 4, and week 24 with baseline skin and joint disease activity and response to therapy were evaluated using generalized linear models and Pearson's product-moment correlation tests.Results. Baseline serum levels of IL-17A and IL-17F were positively correlated with baseline skin disease scores (r = 0.39-0.62). IL-23 levels were correlated with skin disease scores to a lesser extent (r = 0.26-0.31). No significant correlations were observed between these cytokine or CRP levels and baseline joint disease activity. There was no significant association of baseline levels of IL-17A, IL-17F, IL-23, or CRP with therapeutic response to ustekinumab in either the skin or joints. Significant reductions from baseline in levels of IL-17A, IL-17F, and CRP were seen in patients treated with ustekinumab compared to those treated with placebo. Ustekinumab-treated patients in whom 75% improvement in the Psoriasis Area and Severity Index score or 20% improvement according to the American College of Rheumatology criteria was achieved after 24 weeks of treatment had greater reductions in CRP level (geometric mean decreases of 51-58% versus 32-33%; P < 0.05), but not IL-17A or IL-17F levels, than nonresponders.Conclusion. Baseline serum IL-23/IL-17 levels correlated with skin, but not joint, disease activity, suggesting tissue-specific variation. However, neither baseline Th17-associated cytokine levels nor CRP level were predictive of therapeutic response to ustekinumab in the skin or joints, despite rapid reductions in their levels following ustekinumab therapy.ClinicalTrials.gov identifiers: NCT01009086 (PSUMMIT 1) and NCT01077362 (PSUMMIT 2).

show abstract

“…Approximately 25% of patients with psoriasis also develop chronic inflammatory arthritis called psoriatic arthritis [99]. There is currently no method to predict the development of psoriatic arthritis in a patient with only psoriasis before symptoms appear.…”

Section: Psoriatic Arthritismentioning

confidence: 99%

Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations

Chan

Reddy

Myers

et al. 2020

Dermatol Ther (Heidelb)

165

108

View full text Add to dashboard Cite

Machine learning (ML) has the potential to improve the dermatologist's practice from diagnosis to personalized treatment. Recent advancements in access to large datasets (e.g., electronic medical records, image databases, omics), faster computing, and cheaper data storage have encouraged the development of ML algorithms with human-like intelligence in dermatology. This article is an overview of the basics of ML, current applications of ML, and potential limitations and considerations for further development of ML. We have identified five current areas of applications for ML in dermatology: (1) disease classification using clinical images; (2) disease classification using dermatopathology images; (3) assessment of skin diseases using mobile applications and personal monitoring devices; (4) facilitating large-scale epidemiology research; and (5) precision medicine. The purpose of this review is to provide a guide for dermatologists to help demystify the fundamentals of ML and its wide range of applications in order to better evaluate its potential opportunities and challenges.

show abstract

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies

Abstract: We found that 1 in 4 patients with psoriasis have PsA. With the growing recognition of the Classification Criteria for Psoriatic Arthritis, more homogenous and comparable prevalence estimates are expected to be reported.

Cited by 432 publications

References 271 publications

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations

Contact Info

Product

Resources

About